<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546856</url>
  </required_header>
  <id_info>
    <org_study_id>PI14/01208</org_study_id>
    <nct_id>NCT02546856</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients</brief_title>
  <acronym>ETIFIC</acronym>
  <official_title>Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Galdakao-Usansolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Basque Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Galdakao-Usansolo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Heart Failure (HF) generates multiple hospital admissions and mortality, which
      are reduced with the administration of Beta-Blocker (BB), Angiotensin Converting Enzyme
      Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor
      Antagonist (MRA) drugs (Level of Evidence A). The effect is dose-dependent. Nevertheless,
      dosages are suboptimal. European Guidelines 2012 recommend close monitoring and up-titration
      of drugs by HF nurses. Trials are needed to evaluate their effectiveness and safety.
      Objective: To compare doses achieved by patients of BB, ACEI, ARA II and ARM in 4 months ( %
      relative to target doses) in the intervention group (HF nurse) and in the control group (
      cardiologist), adverse events, Left Ventricular Ejection Fraction (LVEF), New York Heart
      Association (NYHA), 6 min. walking test, quality of life, Nt-proBNP, readmissions and
      mortality. Hypothesis: Non-inferiority. Design: Multicenter randomized controlled trial. New
      (&quot;de novo&quot;) HF patients with LVEF ≤ 40%, NYHA II-III, without contraindications to BB of 17
      Spanish hospitals will be included. Intervention: The cardiologist prescribes drugs and,
      driven by protocol, the HF nurse implements the up-titration. In the control group doses are
      decided by the cardiologist clinical support and education being provided by nurses.
      Variables: age, sex, education, psycho-social level, Cardio Vascular Risk Factors (CVRF),
      NYHA, LVEF, ischemic cardiopathy., N-terminal pro B-type natriuretic peptide (Nt-proBNP),
      6min. walking test, Creatinine/Glomedular Filtration Rate (GFR), Potassium (K), haemoglobin,
      Blood Preassure (BP), Heart Rate (HR), mg./drug, European Heart Failure Self-Care Behaviour
      Scale (EHFScBS), Minnesota Living with Heart Failure questionnaire (MLHFQ), European Quality
      of life Scale (EQ-5D). Expected Results: If our hypothesis were confirmed, evidence would be
      provided on the effectiveness of this healthcare management, that could be economically
      evaluated in future studies. A qualitative study also will be undertaken to explore barriers
      and facilitators to implementation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No apply
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BB % relative dose (mean) with regard to target dose</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events described in ESC Guidelines: Creatinine Estimated Glomerular Filtration (EGF)</measure>
    <time_frame>4 months</time_frame>
    <description>Creatinine Estimated Glomerular Filtration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events described in ESC Guidelines: K</measure>
    <time_frame>4 months</time_frame>
    <description>Potassium &gt;= 5.5 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events described in ESC Guidelines: Symptomatic Hypotension</measure>
    <time_frame>4 months</time_frame>
    <description>Symptomatic hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events described in ESC Guidelines: HR</measure>
    <time_frame>4 months</time_frame>
    <description>Heart Rate &lt; 50 b.p.m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events described in ESC Guidelines: Atrio Ventricular (AV) Block</measure>
    <time_frame>4 months</time_frame>
    <description>AV Block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events described in ESC Guidelines: worsening of signs and symptoms</measure>
    <time_frame>4 months</time_frame>
    <description>Worsening of HF signs and symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events: Admissions</measure>
    <time_frame>4 months</time_frame>
    <description>Admissions due to up-titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events: Mortality</measure>
    <time_frame>4 months</time_frame>
    <description>mortality due to up-titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events: Drug Stop</measure>
    <time_frame>4 months</time_frame>
    <description>Drug Stop</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: % LVEF (mean)</measure>
    <time_frame>6 months</time_frame>
    <description>% LVEF Improvement (Increase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: Nt-proBNP</measure>
    <time_frame>6 months</time_frame>
    <description>Nt-proBNP Improvement (Decrease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: 6 minute walking test</measure>
    <time_frame>6 months</time_frame>
    <description>6 minute walking test Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: NYHA class</measure>
    <time_frame>6 months</time_frame>
    <description>New York Heart Association functional classification based on severity of symptoms and physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: Quality of Life: MLHFQ</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life, measured by Minnesota Living with Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: Quality of Life: EQ-5D</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life measured by European Quality of Life Scale: EuroQol EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: nº of admissions due to HF</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible benefits: nº of deaths</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACEI % relative dose (mean) with regard to target dose</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARB % relative dose (mean) with regard to target dose</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRA % relative dose (mean) with regard to target dose</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">628</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF nurse up-titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF nurse up-titration</intervention_name>
    <description>Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 European Society of Cardiology (ESC) HF guidelines with cardiologist prescription and support</description>
    <arm_group_label>HF nurse up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF nurse up-titration</intervention_name>
    <description>Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support</description>
    <arm_group_label>HF nurse up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF nurse up-titration</intervention_name>
    <description>Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support</description>
    <arm_group_label>HF nurse up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF nurse up-titration</intervention_name>
    <description>Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support</description>
    <arm_group_label>HF nurse up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF cardiologist up-titration</intervention_name>
    <description>Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF cardiologist up-titration</intervention_name>
    <description>Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF cardiologist up-titration</intervention_name>
    <description>Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HF cardiologist up-titration</intervention_name>
    <description>Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with &quot;de novo&quot; heart Failure and LVEF &lt;= 40% admitted in hospital, without
             contraindications for BB prescription with cardiologist up-titration prescription and
             without having achieved BB target dose previous discharge and signing informed
             consent.

        Exclusion Criteria:

          -  Contraindications for BB.

          -  Living in a nursing home.

          -  Life expectancy &lt; 6 months.

          -  Unable to self-care or mental disease without caregiver.

          -  Unable to weight

          -  Without phone

          -  Unable to go to clinic visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Juana Oyanguren, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osakidetza-Servicio vasco de Salud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesús Torcal, PhD</last_name>
    <phone>+34618781544</phone>
    <email>jesus.torcallaguna@osakidetza.eus</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iñaki Lekuona, MD</last_name>
    <phone>+34944007105</phone>
    <email>inaki.lekuonagoya@sakidetza.eus</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de usansolo-Galdakao</name>
      <address>
        <city>Usansolo</city>
        <state>Bizkaia</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Juana Oyanguren, Nurse</last_name>
      <phone>+34618781544</phone>
      <email>juanaoy@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Galdakao-Usansolo</investigator_affiliation>
    <investigator_full_name>Maria Juana Oyanguren Artola</investigator_full_name>
    <investigator_title>Heart Failure Nurse</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

